oa Evolving therapeutic strategies in IgA nephropathy: from conservative management to targeted interventions

References

1. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011; 26:414–430. doi: 10.1093/ndt/gfq665
   [Google Scholar]
2. Alkadi MM, Abuhelaiqa EA, Thappy SB, et al.. Kidney biopsy in patients with markedly reduced kidney function. Kidney Int Rep. 2022Aug17; 7:(11):2505–2508. doi: 10.1016/j.ekir.2022.08.004
   [Google Scholar]
3. Ohyama Y, Renfrow MB, Novak J, et al.. Aberrantly glycosylated IgA1 in IgA nephropathy: what we know and what we don’t know. J Clin Med. 2021Aug5; 10:(16):3467. doi: 10.3390/jcm10163467
   [Google Scholar]
4. Le W, Liang S, Hu Y, et al.. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant 2012; 27: doi.org/10.1093/ndt/gfr527
   [Google Scholar]
5. Thompson A, Carroll K, A Inker L, et al.. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019Mar7; 14:(3):469–481. doi: 10.2215/CJN.08600718
   [Google Scholar]
6. Rovin BH, Adler SG, Barratt J, et al.. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 2021; 100:753–79. doi: 10.1016/j.kint.2021.05.015
   [Google Scholar]
7. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436–1446. doi: 10.1056/NEJMoa2024816
   [Google Scholar]
8. The E-KCG, Herrington WG, Staplin N, et al.. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388:117–127. doi: 10.1056/NEJMoa2204233
   [Google Scholar]
9. Wheeler DC, Toto RD, Stefánsson BV, et al.. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021Jul; 100:(1):215–224. doi: 10.1016/j.kint.2021.03.033
   [Google Scholar]
10. Rovin BH, Barratt J, Heerspink HJL, et al.. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023Dec2; 402:(10417):2077–2090. doi: 10.1016/S0140-6736(23)02302-4
    [Google Scholar]
11. Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J; STOP-IgAN Investigators. Intensive supportive care plus Immunosuppression in IgA nephropathy. N Engl J Med. 2015Dec3; 373:(23):2225–2236. doi: 10.1056/NEJMoa1415463
    [Google Scholar]
12. Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Budde K, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J; STOP-IgAN Investigators. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020Oct; 98:(4):1044–1052. doi: 10.1016/j.kint.2020.04.046
    [Google Scholar]
13. Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Jardine MJ, Reich HN, Cattran D, Glassock R, Levin A, Wheeler DC, Woodward M, Billot L, Stepien S, Rogers K, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V; TESTING Study Group. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022May17; 327:(19):1888–1898. doi: 10.1001/jama.2022.5368
    [Google Scholar]
14. Barratt J, Lafayette R, Kristensen J, et al.. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023Feb; 103:(2):391–402. doi: 10.1016/j.kint.2022.09.017
    [Google Scholar]
15. Lafayette R, Kristensen J, Stone A, et al.. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023Sep9; 402:(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14. Erratum in: Lancet. 2023 Sep 9;402(10405):850. doi: 10.1016/S0140-6736(23)01851-2
    [Google Scholar]
16. Peng XJ, Zheng WM, Fu R, Huang YH, Deng MH, Tao SS, Wang TJ, Zhu C. Efficacy and safety of mycophenolate mofetil in the treatment for IgA nephropathy: a meta-analysis of randomized controlled trials. Clin Exp Nephrol. 2021Jul; 25:(7):788–801. doi: 10.1007/s10157-021-02028-5
    [Google Scholar]
17. Hou FF, Xie D, Wang J, Xu X, Yang X, Ai J, Nie S, Liang M, Wang G, Jia N; MAIN Trial Investigators. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. JAMA Netw Open. 2023Feb1; 6:(2):e2254054. doi: 10.1001/jamanetworkopen.2022.54054
    [Google Scholar]
18. Zhang H, Rizk DV, Perkovic V, Maes B, Kashihara N, Rovin B, Trimarchi H, Sprangers B, Meier M, Kollins D, Papachristofi O, Milojevic J, Junge G, Nidamarthy PK, Charney A, Barratt J. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int. 2024Jan; 105:(1):189-199. doi: 10.1016/j.kint.2023.09.027
    [Google Scholar]
19. Perkovic V, Kollins D, Papachristofi O, et al.. Efficacy and safety of iptacopan in patients with primary IgA nephropathy: interim analysis results of the Phase 3 APPLAUSE-IgAN study, Nephrology Dialysis Transplantation, Volume 39:Issue Supplement_1May2024gfae069–0141–456,
    [Google Scholar]
20. El Karoui K, Fervenza FC, De Vriese AS. Treatment of IgA nephropathy: a rapidly evolving field. J Am Soc Nephrol. 2024Jan1; 35:(1):103-116. doi: 10.1681/ASN.0000000000000242
    [Google Scholar]
21. Mathur M, Barratt J, Chacko B, et al.. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med. 2024Jan4; 390:(1):20-31. doi: 10.1056/NEJMoa2305635
    [Google Scholar]